. Interestingly, the cultures of the removed prosthesis were negative.
Unfortunately, 10 months after the second AVR, the patient presented with signs of heart failure (New York Heart Association class III) and hemolysis. TTE showed severe PVL with the risk of prosthesis dehiscence (Figure 1e) . TEE revealed pulsatile perivalvular echo -free space, with a systolic expansion and diastolic collapse typical for valvular aneurysm, which was communicated with the left ventricular outflow tract and resulted in severe PVL ( Figure 1F) . A complex treatment with vancomycin, imipenem, and rifampicin was used.Because of hemodynamic instability, the third AVR was urgently performed
The initial treatment included ciprofloxacin and ceftriaxone, which were upgraded to meropenem and vancomycin. Due to increasing C -reactive protein levels, gentamicin and rifampicin were additionally administered. The sequential blood cultures were negative. Control TTE/TEE after 8 weeks showed no vegetations. The perivalvular infiltration seemed to be more fibrous and the prosthetic gradient was normal. Eighteen months after the diagnosis of infective endocarditis (IE), the patient was readmitted with tachycardia, dyspnea, and hemolytic anemia (hemoglobin, 6.5 g/dl). Urgent TTE/TEE revealed significant perivalvular leak (PVL) in the area of previously detected infiltration ( Figure 1C) . The patient underwent another AVR (SJM Regent, St. Jude Medical, Saint Paul, Minnessota, United with an aortic homograft implantation. Unfortunately, the patient required reoperation and died a few days later. Kidney transplant recipients are especially susceptible to IE, which increases the mortality rates and the risk of graft loss; immunosuppressive therapy is the most important predisposing factor. 1 It should be emphasized that prosthetic valve endocarditis is the most severe form of IE.
2 Patients with valve prostheses and previous IE, especially those on immunosuppressive treatment, have a very high risk of IE, and more often develop complications. 2,3 In addition, immunosuppressive therapy in kidney transplant recipients may lead to an increase in the rate of other complications, such as liver and brain abscess. 1 Importantly, not only vegetations but also new periprosthetic regurgitation found on TTE suggest IE and their cause must always be identified, even in the absence of positive blood cultures. Perivalvular abscess can develop into serious complications, including PVL, fistula, or pseudoaneurysms. 3,4 PVL may cause clinically significant hemolysis and signs of heart failure, which contributes to high in -hospital and 1 -year mortality rates also in renal transplant recipients. 1,2
The sensitivity of TTE and TEE for the diagnosis of perivalvular abscesses is about 50% and 90%, respectively.
3,5 However, small abscesses may be difficult to identify even by TEE, and multislice computed tomography or positron emission tomography -computed tomography are helpful in the diagnosis. 2 To detect and manage possible complications in patients with valve prostheses and a history of IE, especially in those receiving immunosuppressants, frequent echocardiographic follow -up is recommended. Patients with severe perivalvular damage require surgery; however, the hospital mortality rates remain high. 
